Eli Lilly partnered with telehealth provider Hims & Hers Health on November 6, 2026, allowing patients to directly purchase obesity treatments Zepbound and Foundayo at self-pay prices starting at $299 and $149 per month. The deal marks a strategic shift for Hims & Hers away from compounded GLP-1 knockoffs toward FDA-approved drugs, mirroring its March 2026 agreement with rival Novo Nordisk. Following the announcement, Hims & Hers shares rose over 6% in premarket trading.
Eli Lilly and Hims & Hers platform agreement
- ▪Hims & Hers Chief Executive Officer Andrew Dudum expects to expand the platform's partnership with Eli Lilly to offer its experimental obesity drug retatrutide
- ▪Lilly USA president Ilya Yuffa said that as part of the November 6, 2026 deal, Hims & Hers committed to not sell any compounded versions or knockoffs of Eli Lilly obesity medications
- ▪Prior to the November 6, 2026 partnership, Hims & Hers patients had to leave the platform and navigate to LillyDirect to obtain Eli Lilly obesity drugs
- ▪Eli Lilly struck an agreement to offer its obesity drugs Zepbound and Foundayo directly on Hims & Hers Health's telehealth platform
- ▪Under the November 6, 2026 agreement, eligible Hims & Hers customers with prescriptions can access Eli Lilly weight-loss medications at self-pay prices matching LillyDirect
Pricing of weight-loss drugs on Hims & Hers
- ▪On Hims & Hers, Eli Lilly's oral weight-loss drug Foundayo starts at $149 per month self-pay, while injectable obesity drug Zepbound starts at $299 per month
- ▪Novo Nordisk treatments available on Hims & Hers start at $149 per month for the Wegovy pill and $199 per month for the Wegovy injector pen
Market reaction and analyst view
- ▪Leerink Partners analyst Michael Cherny described the November 6, 2026 agreement with Eli Lilly as a clear positive that completes Hims & Hers' effort to secure access to major GLP-1 drugmakers
- ▪Following Eli Lilly and Hims & Hers' November 6, 2026 deal announcement, Hims & Hers shares rose over 6% in premarket trading, while Eli Lilly shares dipped 1.4%
Hims & Hers shift away from compounded drugs
- ▪Hims & Hers previously offered lower-cost compounded GLP-1 weight-loss drugs before adopting a strategy in March 2026 focused on FDA-approved medications
- ▪Hims & Hers formed a distribution partnership with Novo Nordisk in March 2026 to offer Wegovy and Ozempic following past legal friction over compounded drugs
Foundayo market entry and sales performance
- ▪Eli Lilly's obesity pill Foundayo missed quarterly sales estimates for the period ending October 2026, prompting Eli Lilly to launch marketing campaigns including an advertisement featuring Martha Stewart
- ▪Eli Lilly launched its oral obesity medication Foundayo in April 2026, approximately three months after Novo Nordisk introduced its Wegovy pill to the U.S. market
Story comments
Loading comments…